For example, the A2aR small molecule inhibitor Ciforadenant combined with Atezolizumab improved T cell infiltration in patients with renal cell carcinoma resistant to PD-(L)1 antibody therapy Figure 1A (134). The gene discussed is CD274; the disease is hereditary clear cell renal cell carcinoma.